MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Immunohistochemistry or IHC

Often used to diagnose cancer, Immunohistochemistry or IHC is a process by which antibodies are detected in tissue samples by use of a specific antigen or antigens. IHC is also widely used in basic research to understand the distribution and localization of biomarkers in different parts of a tissue (also see “Serum Marker/Blood Test“).

Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.

Biochemical and Biophysical Research Communications 2019 March 5 [Link] Abayasiriwardana KS, Wood MK, Prêle CM, Birnie KA, Robinson BW, Laurent GJ, McAnulty RJ, Mutsaers SE Abstract Malignant mesothelioma is an aggressive fibrous tumor, predominantly of the pleura, with a very poor prognosis. Cell-matrix interactions are recognized important determinants of tumor growth and invasiveness but the […]

Comments Off on Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.

BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.

Applied Immunohistochemistry & Molecular Morphology 2019 January 11 [Link] Erber R, Warth A, Muley T, Hartmann A, Herpel E, Agaimy A Abstract Malignant mesothelioma (MM) can show areas closely mimicking reactive mesothelial proliferations or recapitulating benign adenomatoid tumors (ATs) making distinction on occasion impossible on morphologic ground alone, particularly in limited biopsy material. Recently, loss […]

Comments Off on BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.

Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.

Lung Cancer 2019 January [Link] Chapel DB, Churg A, Santoni-Rugiu , Tsujimura T4, Hiroshima K5, Husain AN Abstract The pathologist plays a central role in the diagnosis and management of malignant mesothelioma, including definitive tissue-based diagnosis in conjunction with clinical and radiographic data; diverse ancillary studies of diagnostic, prognostic, and predictive importance; and research efforts to better define the pathobiology of […]

Comments Off on Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.

EBioMedicine 2018 December 20 [Link] Sciarrillo R1, Wojtuszkiewicz A2, El Hassouni B, Funel N, Gandellini P, Lagerweij T, Buonamici S, Blijlevens M, Zeeuw van der Laan EA, Zaffaroni N, Deraco M, Kusamura S, Würdinger T, Peters GJ, Molthoff CFM, Jansen G, Kaspers GJL, Cloos J, Giovannetti E Abstract INTRODUCTION: Therapeutic options for diffuse malignant peritoneal […]

Comments Off on Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.

The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.

Diagnostic Cytopathology 2018 December 6 [Link] Hatem L, McIntire PJ, He B, Gogineni S, Ho M, Mathew S, Margolskee EM, Siddiqui MT, Rao RA Abstract BACKGROUND: Malignant mesothelioma (MM) is a diagnostically challenging entity in cytology specimens due to the lack of architectural context and a cytomorphologic overlap between malignant and reactive mesothelial cells (RMCs). […]

Comments Off on The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.

Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.

Journal of Immunology Research 2018 October 29 [Link] Tazzari M, Brich S, Tuccitto A, Bozzi F, Beretta V, Spagnuolo RD, Negri T, Stacchiotti S, Deraco M, Baratti D, Camisaschi C, Villa A, Vergani B, Rivoltini L, Pilotti S, Castelli C Abstract Malignant peritoneal mesothelioma (MpM), arising in the setting of local inflammation, is a rare […]

Comments Off on Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.

A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.

Lung Cancer 2018 November [Link] Kinoshita Y, Hamasaki M, Yoshimura M, Matsumoto S, Sato A, Tsujimura T, Ueda H, Makihata S, Kato F, Iwasaki A, Nabeshima K Abstract OBJECTIVES: Histologic diagnosis of malignant pleural mesothelioma (MPM) is not always straightforward. Loss of BRCA1-associated protein 1 (BAP1) expression as detected by immunohistochemistry (IHC) (BAP1 IHC) and […]

Comments Off on A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.

Well-differentiated papillary mesothelioma: A 17-year single institution experience with a series of 75 cases.

Annals of Diagnostic Pathology 2018 October 28 [Link] Sun M, Zhao L, Weng Lao I, Yu L, Wang J Abstract We present our experience with 75 cases of well-differentiated papillary mesothelioma (WDPM) that were diagnosed at our institution between 2000 and 2017. The patients included 58 females and 17 males with age ranging from 18 […]

Comments Off on Well-differentiated papillary mesothelioma: A 17-year single institution experience with a series of 75 cases.

Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.

Medicine 2018 November [Link] Du Z, Yu Y, Wu D, Zhang G, Wang Y, He L, Meng R Abstract RATIONALE: Malignant Pleural Mesothelioma (MPM) is rare cancer and has a poor prognosis with resistance to chemotherapy or radiotherapy. Until now there is no standard third-line treatment for patients who have failed second-line therapy. PATIENT CONCERNS: […]

Comments Off on Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.

MUC21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.

Histopathology 2018 October 17 [Link] Kai Y1,2, Amatya VJ1, Kushitani K, Kambara T, Suzuki R, Tsutani Y, Miyata Y, Okada M, Takeshima Y Abstract AIMS: The process of differential diagnosis between epithelioid mesothelioma and lung adenocarcinoma has been progressing; however, there are no absolute immunohistochemical markers to definitively diagnose epithelioid mesothelioma. The aim of this […]

Comments Off on MUC21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.